I can agree with most of that and its places like Abbvie, CRI, UTSWM, Keystone Symposia, Japan...etc that are taking a big interest in PS Targeting - so keeping an eye on all affiliations surrounding places like these, and research that comes out of each just may help solve this puzzle of how Peregrine advances the, paradigm shifting, anti-PS Technology Platform.
wwtmm, that sounds about as reasonable a conclusion as I've read. Otherwise PPHM's behavior seems inexplicable! Thanks. Also thanks to BKT for putting it all so clearly how so many of us longs feel. Still haven't given up on Kyoto or breast announcements this week.
I echo and appreciate the sentiments expressed by BKT and agree with wwtm that some other entity is likely pulling the strings. I have always thought it has most likely been Roche/Genentech ever since Rob Garnick joined the team (albeit as a consultant). Seems like Roche sent him over to babysit our promising MAB until which time they deemed it appropriate to officially/legally make it ther own. In that scenario I could also envision them having "influenced" the PhII dose switching in such a way as others on this board have speculated to glean good info about the drug's effectiveness while critically injuring Peregrine Pharma to the point where they could pick up the IP for pennies on the dollar (partially worked but did not inflict the critical injury that may have been intended). The company changed and has been in lock down mode with regard to communication since around the time Rob joined. All part of the master plan to stealthily nurture the Golden Egg and then, just prior to hatching, steal it from the goose they have been slowly poisoning along the way. Brilliant! While I am sensitive to CP's argument about the foolishness of doing things to harm one's own investments I quietly (until now anyway) have and will express my displeasure with the lack of communication and promotion of the company in how I vote my shares. Rocker
News 
Market Data 
Discover 
